ADORA2A and brain ischemia: Therefore, future studies are needed to determine whether a combinatorial therapy involving the AMPAR antagonist perampanel and the A2AR blocker istradefylline proves more efficacious than monotherapy to reduce neuroinflammation, neurodegeneration, and behavioral deficits in cerebral ischemia.